What is Calcitonin salmon?
Salmon calcitonin is a hormone medicine that reduces bone breakdown. Injectable and nasal preparations have distinct clinical histories and instructions.
Biological role or research focus
Calcium regulation and bone conditions.
The exact formulation and indication matter; a peptide category does not describe a universal bone treatment.
Role reference: MedlinePlus · Calcitonin salmon ↗
Names you may encounter
calcitonin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Calcium-regulating hormone
- Main research area
- Bone resorption and blood calcium
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Calcitonin salmon FDA approved?
- Yes. Miacalcin injection (NDA 017808) for Paget's disease of bone, hypercalcemia and postmenopausal osteoporosis. Source ↗
- Is Calcitonin salmon safe?
- Older approved hormone drug for Paget's disease, high calcium and osteoporosis; key concerns are serious allergic reactions, low calcium and a possible small increase in cancer risk. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Calcitonin salmon banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| PROOF (2000) | Human randomized trial | 1,255 postmenopausal women with established osteoporosis. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2000
PROOF
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
- Population / model
- 1,255 postmenopausal women with established osteoporosis.
- Study design
- Five-year nasal-spray study; all groups also received calcium and vitamin D.
- Main finding
- The prespecified middle-dose group had fewer new vertebral fractures than placebo: 51/287 versus 70/270; relative risk 0.67. The other dose groups did not significantly differ from placebo.
- Limits & context
- Only 511 participants completed five years. Attrition and the inconsistent dose response matter. Nasal-spray findings should not be transferred automatically to injectable products or every fracture type.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
32 registered studies name Calcitonin salmon as an intervention among the 100 most recently updated of 155 search results; 6 are recruiting or under way, 2 have not started recruiting yet, 15 completed and 9 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 32 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Calcitonin. ↗
· 2006 · Review
Calcitonin Stewardship Strategies. ↗
Journal of pharmacy practice · 2019 Oct · Journal Article, Review
Treatment of postmenopausal osteoporosis. ↗
Pharmacotherapy · 2005 Apr · Journal Article, Review
Primary Osteoporosis Induced by Androgen and Estrogen Deficiency: The Molecular and Cellular Perspective on Pathophysiological Mechanisms and Treatments. ↗
International journal of molecular sciences · 2024 Nov 12 · Journal Article, Review
Read available full text ↗
Risks & interactions
Older approved hormone drug for Paget's disease, high calcium and osteoporosis; key concerns are serious allergic reactions, low calcium and a possible small increase in cancer risk.
Safety comes from FDA-approved labeling (Miacalcin) based on open-label trials lasting several months to two years and a pooled analysis of 21 controlled trials of other calcitonin salmon forms. A long-term cancer risk cannot be ruled out.
Take extra care with: Cancer, now or in the past
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People allergic to calcitonin salmon or any ingredient (reactions have included fatal anaphylaxis)
Interactions
- Lithium: calcitonin can lower lithium levels by increasing its removal in urine
Serious risks
- Serious allergic reactions, including fatal anaphylaxis, bronchospasm and throat swelling
- Low blood calcium with muscle cramps, twitching or seizures
- Possible higher overall cancer risk, seen in a pooled analysis of trials
- Antibodies that may make the drug stop working
- Abnormal urine sediment seen in one study of bed-rested volunteers
Common side effects
- nausea
- vomiting
- injection-site inflammation
- flushing of the face or hands
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Miacalcin (calcitonin salmon) prescribing information ↗
Key precautions
Allergic reactions, including reactions to salmon calcitonin, require attention. The appropriate benefit-risk assessment depends on the indication, formulation, and current prescribing information.
Source: MedlinePlus · Calcitonin salmon ↗
Regulatory status
- U.S. FDA approval
- Approved
Miacalcin injection (NDA 017808) for Paget's disease of bone, hypercalcemia and postmenopausal osteoporosis. Nasal spray products (Miacalcin nasal NDA 020313, Fortical) and Calcimar are listed as discontinued. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The injection reference describes selected osteoporosis, Paget disease, and high-calcium uses. The PROOF study below tested nasal spray in osteoporosis, so its results should be read in that formulation-specific context.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
Calcitonin restrains bone resorption, which differs from the bone-forming approach of teriparatide or abaloparatide. It also influences calcium balance.
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- The exact formulation and indication matter; a peptide category does not describe a universal bone treatment.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Why separate nasal and injectable evidence?
Route and formulation change exposure and the clinical use being tested. A nasal-spray fracture study is not an injection study.
Did every PROOF dose reduce fractures?
No. The prespecified middle-dose group differed from placebo; the other groups did not show statistically significant reductions.
References & editorial record
- MedlinePlus · Calcitonin salmon ↗
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
